Skip to Main content Skip to Navigation
Journal articles

Overview of the Development and Use of Akt Inhibitors in Prostate Cancer

Abstract : Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease.
Complete list of metadata
Contributor : Hal Sorbonne Université Gestionnaire Connect in order to contact the contributor
Submitted on : Tuesday, January 18, 2022 - 10:30:08 AM
Last modification on : Thursday, March 31, 2022 - 3:55:45 AM


Publication funded by an institution



Anis Gasmi, Guilhem Roubaud, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, et al.. Overview of the Development and Use of Akt Inhibitors in Prostate Cancer. Journal of Clinical Medicine, MDPI, 2021, 11 (1), pp.160. ⟨10.3390/jcm11010160⟩. ⟨hal-03531239⟩



Record views


Files downloads